Dealmaking dominated the healthcare and biotech tape, with GSK striking a near-$750 million agreement to bolster its blood cancer pipeline while a smaller diagnostics name found a fresh commercial foothold. The contrast captured the sector's dual rhythm, big pharma buying its way into next-generation oncology science, and micro-cap imaging specialists winning incremental contracts to prove out their platforms.
GSK secures Chimagen T cell-engager for multiple myeloma
GSK (LSE:GSK) has agreed to acquire a trispecific T cell-engager for multiple myeloma from privately held Chimagen Biosciences, in a deal worth up to $750 million comprising an upfront payment plus development and commercial milestones. GSK shares stood at 1843.5p, down 0.59% on the day the deal was disclosed. The asset binds to T cells while targeting two validated tumour-associated antigens, an approach designed to improve on the tolerability profile of existing T cell-engagers, which have shown strong efficacy in multiple myeloma but have proven difficult for patients to withstand.
The agreement hands GSK full global rights to the programme, which is expected to enter phase I trials in 2027. It builds directly on an existing relationship between the two companies: GSK previously acquired CMG1A46, a Chimagen dual CD19/CD20-targeted T cell-engager now in phase I trials for B-cell malignancies and autoimmune disorders. Multiple myeloma is the third most common blood cancer worldwide, with roughly 180,000 new cases diagnosed annually, and remains incurable despite being generally treatable, a backdrop against which GSK cites external forecasts putting the US T cell-engager market for the disease at more than $10 billion by 2032.
"Today's deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer, The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease," said Hesham Abdullah, president at GSK.
The transaction underscores GSK's strategy of repeat-dealing with proven biotech partners rather than one-off asset grabs, a second bite at Chimagen's platform signals genuine confidence in the underlying science, not just opportunistic bolt-on buying. For GSK, it deepens a haematology-oncology pipeline the company has flagged as a growth priority, though the $750 million ceiling is backloaded to milestones, meaning the near-term cash outlay and balance-sheet impact are modest. The real test arrives only once phase I data emerge in 2027, leaving the credibility of this "leadership" claim in blood cancer contingent on clinical execution still years away.
Imaging Biometrics lands second health system win this quarter
Imaging Biometrics (LSE:IBAI) said its US subsidiary has signed an annual subscription agreement with a leading regional health system for its quantitative neuro-oncology imaging software, sending the shares up 14.286% to 0.8p. The platform, comprising IB Neuro, IB Delta T1 and IB FTBx, converts routine MRI scans into standardised, objective biomarkers of tumour biology, replacing the subjective interpretation typical of conventional imaging workflows in brain tumour management.
The healthcare organisation is among the first in its region to adopt these quantitative MRI tools to guide neuro-oncology treatment decisions. "By standardizing the assessment of tumor physiology and treatment response, our platform helps address some of the most significant challenges in brain tumor management," said Michael Schmainda, chief executive of Imaging Biometrics Trevor Brown, chief executive of the London-listed parent, called it "the second major new installation this quarter, testament to our increasingly relevant software."
The repeat pace of installations matters more than the size of any single contract for a company at this stage: two major health system wins inside one quarter suggest the sales pipeline is converting rather than stalling, a signal that will matter more to investors than the subscription value itself as the group works to build a recurring revenue base across US hospital networks.
